文献速递肝病

非选择性β受体阻滞剂通过恢复实验性肝硬化肠道屏障功能减少细菌易位

Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis.
PubMed 文献 · J Hepatol · 2026-07-28

在实验性肝硬化大鼠和小鼠模型中,普萘洛尔减少肝脏16S rDNA负荷及FITC-葡聚糖肠道至肝脏易位,但不减少活菌易位,并恢复黏液上皮和肠道血管屏障完整性。持续β肾上腺素能过度刺激可破坏多层肠道屏障,促进病理性细菌易位。

要点

  • 普萘洛尔减少肝硬化模型中肝脏细菌DNA负荷和FITC-葡聚糖易位,但不减少活菌易位。
  • 普萘洛尔恢复黏液厚度、杯状细胞数量及上皮紧密连接蛋白,改善肠道血管屏障功能。
  • β肾上腺素能过度刺激通过破坏肠道屏障促进细菌易位,部分独立于菌群和血流动力学。

核心结论

  • 持续β肾上腺素能过度刺激破坏多层肠道屏障,促进肝硬化病理性细菌易位。
  • 普萘洛尔通过稳定内皮VE-钙黏蛋白等机制恢复屏障完整性,至少部分独立于菌群改变和血流动力学效应。

研究设计与样本

  • 研究在CCl4和胆管结扎(BDL)诱导的肝硬化大鼠及BDL小鼠中进行,给予普萘洛尔或溶媒对照。
  • 使用异丙肾上腺素构建慢性β肾上腺素能刺激小鼠模型,并使用VE-钙黏蛋白功能获得小鼠进行机制实验。

主要发现

  • 普萘洛尔降低两种肝硬化模型中肝脏16S rDNA负荷和FITC-葡聚糖肠道至肝脏易位,但不减少活菌易位。
  • 普萘洛尔恢复黏液上皮完整性,增加黏液厚度、杯状细胞数量及上皮紧密连接蛋白。
  • 普萘洛尔改善肠道血管屏障功能障碍,降低PV1表达并使BDL小鼠病理性FITC-白蛋白外渗正常化,对VE-钙黏蛋白和claudin-5的影响呈模型依赖性。
  • 无肝损伤时,异丙肾上腺素重现肠道屏障破坏和肠道至肝脏易位而不改变菌群,这些效应被普萘洛尔减弱。
  • VE-钙黏蛋白功能获得小鼠免受β肾上腺素能诱导的屏障破坏,并在BDL后显示肠道至肝脏易位减少。

临床怎么用

  • 非选择性β受体阻滞剂可能通过恢复肠道屏障功能减少肝硬化病理性细菌易位,为其在肝硬化中的获益提供机制解释。
  • 该发现提示非选择性β受体阻滞剂可作为针对肠肝轴的关键病理生理通路的非病因性治疗,但临床转化需进一步验证。

局限性

  • 研究为实验性肝硬化动物模型,结论外推至人类肝硬化需谨慎。
  • 普萘洛尔减少FITC-葡聚糖易位但不减少活菌易位,屏障恢复对临床结局的影响尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Intestinal barriers that limit gut-to-liver translocation of bacteria and bacterial products are disrupted in cirrhosis. Cirrhosis is characterised by sustained β-adrenergic overactivity, which may contribute to barrier dysfunction; however, its impact on the gut-liver axis remains unclear. We investigated whether β-adrenergic signalling drives barrier disruption in experimental cirrhosis and whether this can be targeted with non-selective β-blockers such as propranolol. METHODS: Cirrhosis was induced in rats (CCl4, BDL) and mice (BDL), followed by treatment with propranolol or vehicle. Chronic β-adrenergic stimulation was modelled using isoproterenol in mice, and VE-cadherin gain-of-function mice were used for mechanistic experiments. Barrier integrity and bacterial translocation were assessed by gut-to-liver FITC-dextran translocation, FITC-albumin endomicroscopy, hepatic 16S rDNA, faecal albumin, and junctional immunofluorescence. Ileal transcriptomics, microbiota profiling, primary intestinal endothelial cells, and human ileal organoids were also used. RESULTS: Propranolol reduced hepatic 16S rDNA load and gut-to-liver translocation of FITC-dextran, but not viable bacteria, in both cirrhosis models. It restored muco-epithelial integrity, increasing mucus thickness, goblet cell number, and epithelial tight-junction proteins. Propranolol improved gut-vascular barrier dysfunction, reducing PV1 expression and normalising pathological FITC-albumin extravasation in BDL mice, with model-dependent effects on VE-cadherin and claudin-5. In the absence of liver injury, isoproterenol recapitulated intestinal barrier disruption and gut-to-liver translocation without altering the microbiota; these effects were attenuated by propranolol. VE-cadherin gain-of-function mice were protected from β-adrenergic-induced barrier disruption and showed reduced gut-to-liver translocation after BDL. Ileal transcriptomic alterations were partially reversed in pathways related to barrier function, inflammation, and adrenergic signalling. CONCLUSIONS: Sustained β-adrenergic hyperstimulation disrupts the multilayered intestinal barrier, promoting pathological bacterial translocation in cirrhosis. Propranolol restores barrier integrity through mechanisms involving endothelial VE-cadherin stabilisation, at least partly independently of microbiota changes and haemodynamic effects. IMPACT AND IMPLICATIONS: Intestinal barrier dysfunction is a pathophysiological hallmark that fuels gut-liver axis activation, which in cirrhosis is associated with detrimental complications. Cirrhosis is also characterised by splanchnic sympatho-adrenergic hyperactivity, whose impact on the multilayered intestinal barrier has not been fully dissected. Our finding that β-adrenergic hyperstimulation is a critical driver of intestinal barrier disruption in cirrhosis, leading to pathological bacterial translocation and gut-liver axis activation, provides a potential mechanistic explanation for the beneficial effects of non-selective beta-blockers in cirrhosis and positions them as non-aetiological therapies targeting a key pathophysiological pathway. Given that intestinal barrier disruption and sympatho-adrenergic hyperactivity occur across a range of diseases and clinical conditions, non-selective β-blockers may represent an inexpensive and safe therapeutic approach to stabilise the gut-liver axis beyond cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Castillo E, Felber M, Paule L, et al. Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis. J Hepatol. 2026. PMID: 42521089. doi:10.1016/j.jhep.2026.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。